High Performance Nanoparticle-Based MRI Contrast Agent
Theragnostic Technologies Inc, NY, United States
We have developed a novel nanoparticle-based MRI contrast agent that shows efficacy an order of magnitude higher than current clinical MRI contrast agents, and is safe for use in patients with kidney problems for whom current clinical MRI contrast agents are restricted for use.
Primary Application Area: Biotech & Biological Sciences
Technology Development Status: Prototype
Technology Readiness Level: TRL 3
FIGURES OF MERIT
Value Proposition: This technology, upon complete development, will be the first FDA-approved MRI CA specifically for diagnosis and monitoring of renal failure, thereby overcoming the significant limitation of currently available clinical CT and MRI CAs.
Organization Type: Early-stage Startup (Seed)
Showcase Booth #: 23M - 58T
GOVT/EXTERNAL FUNDING SOURCES
Government Funding/Support to Date: STTR Phase 1 - National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, $150,000, 2013-2014 (1 year)
Primary Sources of Funding: Angel, Friends, Family, Personal Savings, Federal Grant, University, Other
Looking for: Both Funding and Development Partners